ESSERRE
LIVE

Serial Number

79365506

Owner

ESSERRE PHARMA S.R.L.

Attorney

Larry H. Tronco

Filing Date

Dec 2, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ESSERRE Trademark

Serial Number: 79365506 • Registration: 7435507

ESSERRE is a trademark filed by ESSERRE PHARMA S.R.L. on December 2, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

ESSERRE PHARMA S.R.L.

Via Flaminia Nuova n. 260

Entity Type: 99

Trademark Details

Filing Date

December 2, 2022

Registration Date

July 9, 2024

Published for Opposition

April 23, 2024

Goods & Services

Pharmaceutical and natural medicines for the treatment of cardiometabolic and cardiovascular risk factors, vascular disease, gastrointestinal disorders, inflammation and edema of tissues, flu, cough and cold, fatigue, malnutrition, sarcopenia, immune system deficiencies, allergy, hypovitaminosis, cognitive impairment, mental disorders, sleep disorders, musculoskeletal aches, osteoarticular disorders, skin disorders, nails and hair disorders, electrolyte imbalances, anemia, mineral deficiency, headache, urogenital disorders, gynecological disorders, infertility, dental disorders, hepatobiliary disorders, pancreatic disorders, liver disease, obesity, diabetes, eye disease, respiratory system disease, ulcers, trauma; Food supplements and dietary preparations being dietary supplements for the treatment of cardiometabolic and cardiovascular risk factors, vascular disease, gastrointestinal disorders, inflammation and edema of tissues, flu, cough and cold, fatigue, malnutrition, sarcopenia, immune system deficiencies, allergy, hypovitaminosis, cognitive impairment, mental disorders, sleep disorders, musculoskeletal aches, osteoarticular disorders, skin disorders, nails and hair disorders, electrolyte imbalances, anemia, mineral deficiency, headache, urogenital disorders, gynecological disorders, infertility, dental disorders, hepatobiliary disorders, pancreatic disorders, liver disease, obesity, diabetes, eye disease, respiratory system disease, ulcers, trauma; Pharmaceutical products, namely, skin lotions and dermatological preparations

Chemical and organic compositions in the nature of fruit extracts and nutraceuticals for the manufacture of food and drink; Chemical substances, chemical materials and preparations, and natural elements being fruit extracts and nutraceuticals for use in the manufacture of food supplements and cosmetics; Chemical compounds and materials for use in science, namely, reagents for scientific use; Chemical compounds and materials being additives for use in the manufacture of cosmetics; Chemicals for use in the manufacture of pharmaceuticals; Plant extracts for use in the manufacture of pharmaceutical products; Vitamins for use in the manufacture of pharmaceutical products; chemicals for use in the manufacture of food supplements; Plant extracts for use in the manufacture of food supplements; plant extracts for use in the food industry, namely, plant extracts in the manufacture of foods; plant extracts for use in the manufacture of cosmetics; Botanical extracts, other than essential oils, for use in the manufacture of cosmetics

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 5, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 18, 2024 FICS
FINAL DISPOSITION PROCESSED
Dec 18, 2024 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 9, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 9, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 9, 2024 R.PR
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 2, 2024 NONP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 25, 2024 NPUB
NOTIFICATION PROCESSED BY IB
Apr 23, 2024 GPNX
PUBLISHED FOR OPPOSITION
Apr 23, 2024 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 3, 2024 OPNS
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 3, 2024 NONP
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 3, 2024 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 15, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 15, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 15, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 15, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 15, 2024 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 9, 2024 GNFN
FINAL REFUSAL E-MAILED
Mar 9, 2024 GNFR
FINAL REFUSAL WRITTEN
Mar 9, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 24, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 23, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 23, 2024 TROA
REFUSAL PROCESSED BY IB
Oct 25, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 3, 2023 RFCS
REFUSAL PROCESSED BY MPU
Oct 3, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 21, 2023 RFCR
NON-FINAL ACTION WRITTEN
Sep 20, 2023 CNRT
ASSIGNED TO EXAMINER
Sep 12, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 24, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 20, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 16, 2023 REPR